Related Experiment Videos
[Ochratoxins: Molecular strategies for developing an antidote]
Daniel R. McMasters1, Angelo Vedani
1Biografik Labor 3R, CH-Basel.
ALTEX
|February 15, 2001
Summary
Ochratoxin A (OcA) toxicity may not stem from phenylalanine-t-RNA synthetase inhibition. Instead, OcA binds serum albumin, influencing its body retention and toxic effects, suggesting albumin as a therapeutic target.
Area of Science:
- Toxicology
- Biochemistry
- Computational Chemistry
Background:
- Ochratoxin A (OcA) is a mycotoxin with significant nephrotoxic, genotoxic, and carcinogenic effects.
- Previous theories implicated OcA's toxicity to phenylalanine-t-RNA synthetase inhibition.
Purpose of the Study:
- To investigate the primary molecular target of Ochratoxin A.
- To explore OcA's interaction with serum albumin for potential therapeutic strategies.
Main Methods:
- Molecular dynamics simulations of OcA interactions with phenylalanine-t-RNA synthetase and serum albumin.
- Analysis of binding affinities and modes.
Main Results:
- OcA exhibits low millimolar affinity for phenylalanine-t-RNA synthetase, challenging its role as the primary target.
- OcA preferentially binds to serum albumin in vivo, affecting its toxicokinetics and retention.
- Simulations revealed OcA's binding interactions with serum albumin.
Conclusions:
- Serum albumin, not phenylalanine-t-RNA synthetase, is likely the primary in vivo target for OcA.
- Modulating OcA's binding to albumin could reduce its retention and mitigate toxicity.
- Developing synthetic antagonists for albumin binding is a promising therapeutic avenue.